Edition:
United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

0.54USD
27 Jul 2016
Change (% chg)

-- (--)
Prev Close
$0.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
233,288
52-wk High
$2.49
52-wk Low
$0.47

Select another date:

Tue, Jul 19 2016

BRIEF-Navidea gets IRB nod for Lymphoseek rheumatoid arthritis trial protocol

* Navidea receives IRB approval for its Lymphoseek rheumatoid arthritis clinical trial protocol

BRIEF-Navidea Biopharma says continuing to explore alternative financing to refinance some debt

* Received letter dated May 31, 2016 from Capital Royalty Partners II L.P and Capital Royalty Partners II Parallel Fund A L.P. (CRG)

BRIEF-Navidea says received unsolicited offer to refinance CRG loan facility

* Received an unsolicited offer to refinance entire existing CRG loan facility

BRIEF-Navidea reports Q1 loss per share of $0.02

* Expects to begin grant-funded phase 1/2 evaluation of lymphoseek - iv in kaposi's sarcoma patients in second half of 2016

BRIEF-Navidea Biopharmaceuticals says received demand for arbitration from CEO Ricardo Gonzalez

* On May 12, received a demand for arbitration from Ricardo Gonzalez, company's chief executive officer - sec filing

BRIEF-Navidea Biopharmaceuticals files for non-timely 10-Q

* Navidea Biopharmaceuticals Inc files for non-timely 10-Q Source text: http://1.usa.gov/1T9HjVJ Further company coverage:

BRIEF-Navidea and Macrophage Therapeutics to provide development program update

* Navidea and Macrophage Therapeutics to provide development program update Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Navidea Biopharmaceuticals received notice from Capital Royalty Partners II L.P pursuant to term loan agreement, dated May 8, 2015

* On april 7, 2016 received notice from capital royalty partners ii l.p pursuant to term loan agreement, dated may 8, 2015

BRIEF-Navidea Biopharmaceuticals appoints Michael Goldberg chairman of board

* Michael Goldberg appointed as new chairman of board - sec filing

BRIEF-Navidea biopharmaceuticals files for non-timely 10-K

* Files for non-timely 10-k - sec filing Source text : http://1.usa.gov/1QYtREz Further company coverage:

Select another date: